Introduction
============

Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women worldwide, with an estimated 527,600 new cases and 265,700 deaths occurred in 2012 [@B1]. Of these, less economically developed countries account for \~ 84% of cases and \~87% of deaths [@B1]. In more developed countries, the widespread use of Papanicolaou smear screening, which allows early detection and treatment of pre-cancerous lesion, has dramatically declined the incidence rate [@B2]; however, it is still the ninth leading cause of cancer death in the developed regions and an estimated 35,500 women\'s lives were still threatened by this disease in 2012 [@B1]. The prognosis of cervical cancer largely depends on the stage at diagnosis [@B3]. Patients with early-stage disease (FIGO stage I and II) have a high cure rate of 80-95%, but the rate drops to 60% for stage III patients [@B3]. Recurrence is another poor prognosis factor for cervical cancer [@B4]. The recurrence rate ranges from 8% to 26%, and most of recurrences (62-89%) occur within the first two years after primary treatment [@B5]. The 5-year overall survival rate after recurrence (SAR) is only 10.1% to 22.3% [@B6], [@B7]. Early detection of recurrence has been supposed to improve the survival of the patients [@B5]. However, the benefit of salvage therapy for recurrence is still limited and the availability of treatment options largely depends on previous therapy received [@B8]. Therefore, identification of prognostic factors, which could predict recurrence and allow appropriate primary treatment for patients with high-risk, is of great importance for improving the outcome of cervical cancer patients.

The Fez family zinc finger protein 1 (FEZF1) is a C2H2 zinc finger transcription factor that plays critical roles during forebrain and olfactory system development in vertebrates [@B9]. In mice, Fezf1 binds to and represses the expression of *Hes5*, a transcription factor that inhibits neuronal differentiation, to facilitate neurogenesis in the forebrain [@B10]. Recently, FEZF1 has also been implicated in the progression of human cancers [@B11], [@B12]. A 2- to 20-fold increase of FEZF1 expression was observed in more than 50% of gastric cancer tissues when compared to their adjacent normal tissues [@B11]. Then, the upregulation of FEZF1 was also reported in colorectal cancer [@B12]. In gastric cancer cells, FEZF1 was found to enhance proliferation and tumorigenic ability by binding to and activating oncogene *K-ras* [@B11]. In addition, FEZF1 was also shown to promote cell migration and invasiveness in colorectal cancer cells [@B12]. However, the clinical significance of FEZF1 and its target genes in human cancers are still largely unknown.

In present study, we revealed the prominently clinical significance of FEZF1 in cervical cancer by analyzing gene expression data of eight most common cancer types from The Cancer Genome Atlas (TCGA). The effects of FEZF1 on cervical cancer cells were examined both*in vitro* and *in vivo*. Moreover, we also demonstrated that FEZF1 may exert its function by binding to and activating genes in the Wnt signaling pathway.

Materials and Methods
=====================

TCGA datasets
-------------

Clinical and RNAseq gene expression (HiSeqV2) data of eight cancer types, including breast cancer (BRCA), cervical cancer (CESC), colon and rectal cancer (COADREAD), esophageal cancer (ESCA), liver cancer (LIHC), lung cancer (LUNG), prostate cancer (PRAD) and stomach cancer (STAD) were downloaded from the TCGA hub, UCSC Xena (<https://xenabrowser.net/datapages/>). Only data of the primary tumor samples were used for analysis in this study. In survival analysis for CESC, COADREAD, ESCA, LUNG and STAD, patients with detectable FEZF1 expression, overall survival (OS) and recurrence-free survival (RFS) data were included. The patients were divided into high- and low-FEZF1 expression groups according to the Youden index determined using FEZF1 expression values and OS data. For BRCA, LIHC and PRAD, patients with both OS and RFS data were included. And the patients were simply divided in to FEZF1-present or -absent groups. To analysis the associations between FEZF1 expression and the clinicopathological characteristics in CESC, five patients with undefined clinical stage were excluded, and Cox proportional hazards regression analysis was carried out with the same set of CESC patients.

Cell culture
------------

Human cervical cancer cell lines C33A, SiHa and HeLa, and embryonic kidney cell line 293T (HEK293T) were purchased from the Cell bank of the Chinese Academy of Sciences (Shanghai, China). C33A cells were cultured in MEM (Gibco, Grand Island, NY, USA). SiHa, HeLa and HEK293T cells were cultured in DMEM (Gibco). All media were supplemented with 10% fetal bovine serum (FBS, ExCell, Hangzhou, China), 100 U/ml penicillin and 100 μg/ml streptomycin (HyClone, Logan, UT, USA).

Cells were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer\'s protocol. For generation of short hairpin RNA (shRNA) lentiviruses, HEK293T cells were co-transfected with pLKO.1 shRNA vectors and packaging plasmids, psPAX2 and pMD2.G. For FEZF1 knockdown, C33A and SiHa cells were transduced with shRNA lentiviruses and selected by 1 μg/ml puromycin (Sigma-Aldrich, St Louis, MO, USA) for 3 days. After selection, cell pools were grown in culture media without puromycin for 24 h before further analysis. For the expression of FEZF1, HeLa cells were transfected with FEZF1 expression plasmid and subjected to analysis 24 h after transfection.

Plasmid construction
--------------------

For RNA interference, shRNA expression vectors were generated by annealing and inserting shRNA oligonucleotide pairs into pLKO.1 vector. The target sequences of shFEZF1-1 and shFEZF1-2 are 5\'GGTCTTTAATGCGCACTAT3\' and 5\'GTGGTTCATTATGGATGAT3\', respectively. The sequence in the non-target control shCTRL is 5\'CAACAGCCACAACGTCTAT3\'. For the expression of FEZF1, the human codon-optimized cDNA sequence of FEZF1 open reading frame (ORF) was synthesized by Genewiz Inc. (Suzhou, China) with a FLAG tag sequence fused in-frame to the 3\' end of the ORF. Then, the cDNA was cloned into pEGFP-C1 and fused in-frame to the C-terminal of the EGFP ORF (pEGFP-FEZF1).

Reverse transcription-quantitative PCR (RT-qPCR)
------------------------------------------------

RNA was extracted using TRIzol reagent (Invitrogen), treated with DNase I (Thermo Fisher Scientific, Rockford, IL, USA) and converted into cDNA using random hexamer primers and RevertAid M-MuLV reverse transcriptase (Thermo Fisher Scientific). cDNA was quantified using SYBR green I master mix (Foregene, Chengdu, China) and gene-specific primers on the StepOnePlus System (Applied Biosystems, Foster City, CA, USA). PCR amplification reactions were all run in triplicates for each cDNA sample. For comparison, RNA level was first normalized to B2M mRNA, and the relative level of RNA was determined by setting controls as 1. The qPCR primers are listed in Table [S1](#SM0){ref-type="supplementary-material"}.

Western blot analysis
---------------------

Western blot was performed according to standard methods. In brief, proteins were separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto PVDF membranes (Bio-Rad Laboratories, Hercules, CA, USA) and incubated overnight at 4°C with corresponding antibodies: anti-FLAG M2-HRP (1:2000; A8592, Sigma-Aldrich), anti-GAPDH-HRP (1:30000; HRP-60004, Proteintech, Chicago, IL, USA) and anti-β-catenin (1:1000; 617832, Zen BioScience, Chengdu, China). An HRP-conjugated sheep anti-rabbit IgG secondary antibody (1:5000; SA00001-2, Proteintech) was also used for the detection of β-catenin. Protein signal was detected using ECL chemiluminiscent substrate (Thermo Fisher Scientific).

Cell Counting Kit-8 (CCK-8) and colony formation assay
------------------------------------------------------

Cell proliferation was measured by CCK-8 (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer\'s recommendations. Briefly, C33A, SiHa and HeLa cells were seeded in triplicates in 96-well plates at 7000, 2000 and 2000 cells/well, respectively. Cell culture media were changed into fresh media containing 10% (v/v) CCK-8 reagent at indicated times. After a 2 h incubation under the culture condition, the absorbance at 450 nm of each well was measured on a microplate reader. The mean value of the wells with media alone was used as background and was subtracted from the absorbances of the wells containing cells.

For colony formation assay, C33A, SiHa and HeLa cells were seeded at 600, 600 and 400 cells/well respectively in 6-well plates and cultured for 12 days. Cell colonies were fixed with 4% paraformaldehyde for 10 min, stained with 0.1% crystal violet for 5 min and washed twice with phosphate‑buffered saline (PBS). The number of colonies containing more than 50 cells was counted.

Transwell migration assay
-------------------------

For migration assay, Transwell-24 Well Permeable Supports (Corning, Bedford, MA, USA) with 8 μm pores were used. C33A (1×10^5^ cells), SiHa (2×10^4^ cells) and HeLa (5×10^4^ cells) cells were seeded in the upper chambers with media containing 1% FBS. The lower chambers were filled with media containing 20% FBS. After cultured for 20 h, cells on the upper side of the support membranes were wiped out with a cotton swab. Cells on the lower side were fixed with 4% paraformaldehyde for 15 min, stained with 1% crystal violet for 10 min and counted under a microscope (Olympus).

Tumorigenesis in nude mice
--------------------------

Female BALB/c nude mice (5 weeks old) were housed and maintained under special pathogen-free (SPF) condition. C33A cells (5×10^6^) were injected subcutaneously into right flanks of nude mice (n=6 for each group). Tumors were measured every 3 days with a slide caliper and tumor volumes were calculated by the formula: volume (mm^3^) = 0.5 ×length× width^2^. After 30 days, mice were sacrificed, and tumors were dissected, photographed, and weighted.

Gene ontology (GO) enrichment analysis and Pathview visualization
-----------------------------------------------------------------

ChIP (chromatin immunoprecipitation)-seq data of FEZF1 under series accession number GSE76495 were obtained from Gene Expression Omnibus (GEO). To reduce the background, only binding sites with scores over the mean were included for further analysis. GO enrichment analysis of the FEZF1-binding genes was performed using clusterProfiler [@B13], an R/Bioconductor package. Then, the redundancy of the enriched GO terms was reduced using GOSemSim package, which computes the semantic similarity among GO terms [@B14]. Pathview package based on KEGG pathways [@B15] was used for the visualization of FEZF1-binding genes in the Wnt signaling pathway.

ChIP assay
----------

HeLa cells (2×10^7^ cells) were crosslinked in 1% formaldehyde for 30 min at room temperature. The crosslinking was quenched by glycine at a final concentration of 0.125 M for 5 min. The crosslinked cells were sonicated for 20 min on ice in 1ml ChIP buffer (25 mM Tris \[pH 8.0\], 0.15 M NaCl, 0.5% NP-40, 0.1% SDS, 0.5 mM DTT and 1× complete protease inhibitors \[Roche, Indianapolis, IN, USA\]). Then, cell lysates were incubated with 50 μl anti-FLAG M2 magnetic beads (Sigma-Aldrich) at 4°C overnight with rotation. After five washes with ChIP buffer, the beads were resuspended in 0.2 ml SDS buffer (25 mM Tris \[pH 8.0\], 0.2 M NaCl and 1% SDS) to elute the protein-DNA complexes. Then, crosslink was reversed at 65°C overnight, and DNA was recovered by phenol/chloroform extraction and subjected to qPCR analysis. The primers used in qPCR are also listed in Table [S1](#SM0){ref-type="supplementary-material"}.

Statistical analysis
--------------------

All statistical analyses were carried out using SPSS Statistics version 20 (IBM). Data are presented as mean± standard deviation of three independent experiments. Differences in patient survival were assessed by the Kaplan-Meier method and compared using the log-rank test. The differences of means between groups were determined using two-tailed Student t-test or one-way analysis of variance (ANOVA). The correlation between FEZF1 level and the clinicopathological characteristics was analyzed using two-tailed Pearson\'s chi-square test. Univariate and multivariate Cox proportional hazards models were utilized to estimate the relative risk ratio for each factor. *P* \< 0.05 was considered statistically significant. \**P* \< 0.5 and \*\**P* \< 0.01.

Results
=======

FEZF1 expression prominently associated with the RFS of cervical cancer patients in TCGA
----------------------------------------------------------------------------------------

We first examined FEZF1 expression in eight types of human cancers with high incidence and mortality rates worldwide, including BRCA, CESC, COADREAD, ESCA, LIHC, LUNG, PRAD and STAD, using RNAseq gene expression data from TCGA. FEZF1 was detected in most of primary tumor samples from CESC, COADREAD, ESCA, LUNG and STAD, but only in a small portion of the samples from BRCA, LIHC and PRAD (Figure [1](#F1){ref-type="fig"}A). To explore its clinical relevance, we analyzed the relation of FEZF1 expression with the OS and RFS of patients in all these eight cancer types by Kaplan-Meier method. The results showed that FEZF1 expression significantly associated with the OS of CESC, ESCA and LUNG patients, as well as the RFS of CESC and PRAD patients, but no significant association was observed in other cancer types (Figure [S1](#SM0){ref-type="supplementary-material"}), including COADREAD and STAD, in which FEZF1 has been reported to enhance cancer cell aggressiveness. Among all these cancer types, the expression of FEZF1 exhibited a prominent influence on the survival of CESC patients (Figure [1](#F1){ref-type="fig"}B). The 5-year OS rates for patients expressing high- and low-level of FEZF1 were 47% and 75.8% in CESC, respectively. Meanwhile, the 5-year RFS rate was 89.9% for patients with low level of FEZF1 and drops to only 22% for patients with high level of FEZF1. Thus, we focused on and further characterized the clinical significance of FEZF1 in cervical cancer.

FEZF1 was an independent diagnostic factor for cervical cancer recurrence in TCGA patients
------------------------------------------------------------------------------------------

We first examined FEZF1 expression in CESC patients with different clinicopathological characteristics. The results demonstrated that FEZF1 expressed at a significantly higher level in the samples from patients with relapse compared to the samples from patients without diagnosed recurrence (*P*=0.015; Figure [1](#F1){ref-type="fig"}C), but no difference of FEZF1 expression was observed between patient groups with other characteristics, including age, histologic type, histologic grade, clinical stage, pathological T stage and pathological N stage (Table [S2](#SM0){ref-type="supplementary-material"}). We also examined the correlation between FEZF1 level and the clinicopathological characteristics. Similarly, high level of FEZF1 expression associated with recurrence (*P*=0.003, Chi-square test) but not with the other characteristics (Table [S3](#SM0){ref-type="supplementary-material"}). By univariate Cox proportional hazards regression analysis, we found that clinical stage, pathological T stage, pathological N stage and FEZF1 expression were prognostic factors for the OS of CESC patients, and pathological N stage and FEZF1 expression were prognostic factors for the RFS of CESC patients (Table [1](#T1){ref-type="table"}). Then, we performed multivariate analysis for these risk factors. The results showed that FEZF1 expression was an independent diagnostic factor for both the OS and RFS of CESC patients (Table [2](#T2){ref-type="table"}). When taking recurrence into account in the multivariate analysis for the OS, FEZF1 expression was no longer an independent risk factor (Table [S4](#SM0){ref-type="supplementary-material"}), which suggests that FEZF1 influences the OS through its effect on recurrence. Overall, we demonstrated that FEZF1 expression associated with recurrence and was an independent diagnostic marker for recurrence in cervical cancer. Patients with high level of FEZF1 were at higher risk of recurrence (HR=3.479; 95% CI, 1.553-7.795; *P*=0.002) than patients with low level of FEZF1 expression (Table [2](#T2){ref-type="table"}).

FEZF1 knockdown inhibited cervical cancer cell proliferation, growth and migration
----------------------------------------------------------------------------------

To investigate the function of FEZF1 in cervical cancer cells, we knocked down FEZF1 in C33A and SiHa cells by RNA interference using two independent shRNAs (Figure [2](#F2){ref-type="fig"}A). We first measured the effect of FEZF1 on cell proliferation by CCK-8 assay. The results showed that FEZF1 knockdown significantly decreased cell proliferation in C33A and SiHa cells (Figure [2](#F2){ref-type="fig"}B). Then, colony formation assay was performed to measure the continued growth capacity of these cells. As shown in Figure [2](#F2){ref-type="fig"}C, FEZF1 knockdown cells formed significantly less colonies compared to their control cells. We also examined the effect of FEZF1 on cell migration by Transwell assay. The results showed that cell migration ability was attenuated by FEZF1 knockdown in C33A and SiHa cells (Figure [2](#F2){ref-type="fig"}D).

FEZF1 knockdown inhibited cell growth *in vivo*
-----------------------------------------------

To test FEZF1 function *in vivo*, we performed tumorigenesis assay by subcutaneous injection of C33A cells into right flanks of nude mice. In the course of tumor development, the growth of tumors was decelerated by FEZF1 knockdown in C33A cells (Figure [3](#F3){ref-type="fig"}A). At 30 days post-injection, tumors were dissected and weighted. Tumors generated by FEZF1 knockdown C33A cells were much smaller and lighter than the tumors of control cells (Figure [3](#F3){ref-type="fig"}B and [3](#F3){ref-type="fig"}C). The results indicated that FEZF1 has the ability to promote cervical cancer cell growth *in vivo*.

Expression of FEZF1 promoted cell proliferation, growth and migration in HeLa cells
-----------------------------------------------------------------------------------

To further confirm the function of FEZF1, we ectopically expressed a FLAG tagged EGFP-FEZF1 fusion protein in HeLa cells (Figure [4](#F4){ref-type="fig"}A), in which FEZF1 is not expressed endogenously. The effect of FEZF1 on cell proliferation was examined by CCK-8 assay. The result showed that the expression of FEZF1 promoted cell proliferation in HeLa cells (Figure [4](#F4){ref-type="fig"}B). Meanwhile, FEZF1-expressing HeLa cells formed more colonies than the control cells in colony formation assay (Figure [4](#F4){ref-type="fig"}C). In addition, Transwell assay revealed that cell migration ability was also enhanced by FEZF1 expression in HeLa cells (Figure [4](#F4){ref-type="fig"}D).

FEZF1 bound to multiple key genes in the Wnt signaling pathway in HeLa cells
----------------------------------------------------------------------------

In a recent study that characterized C2H2 zinc finger proteins, the genomic binding sites of FEZF1 were determined in HEK293 cells by ChIP-seq analysis [@B16]. To gain insight into the molecular function of FEZF1, we preformed GO enrichment analysis for FEZF1 target genes. In consistence with its function in nervous system development, the result showed that FEZF1 mainly binds to genes involved in neuronal differentiation, epithelial cell migration and developmental growth, as well as genes in the Wnt signaling pathway (Figure [5](#F5){ref-type="fig"}A). The binding of FEZF1 to the Wnt signaling pathway genes was visualized by the Pathview package based on KEGG pathways. As shown in Figure [5](#F5){ref-type="fig"}B, FEZF1 bound to dozens of genes in both canonical and non-canonical Wnt pathways. To determine whether FEZF1 binds to these Wnt pathway genes in cervical cancer cells, we performed ChIP assay in HeLa cells expressing the FLAG tagged EGFP-FEZF1 protein. Consistent with the ChIP-seq study in HEK293 cells, the result showed that FEZF1 bound to multiple key Wnt pathway genes in HeLa cells (Figure [5](#F5){ref-type="fig"}C), suggesting a regulatory role of FEZF1 in the Wnt pathway in cervical cancer cells.

FEZF1 activated the Wnt signaling pathway in cervical cancer cells
------------------------------------------------------------------

We further investigated the effects of FEZF1 on the Wnt signaling pathway in cervical cancer cells. β-catenin protein, encoded by *CTNNB1* gene, is the core component of the canonical Wnt pathway (also known as Wnt/β-catenin pathway). Upon activation by upstream signals, β-catenin accumulates, binds to and activates TCF/LEF (T-cell factor/lymphoid enhancing factor) transcription factors in the nucleus, which leads to the activation of the downstream genes that are involved in cell proliferation and growth, such as *JUN* and *CCND1*. Therefore, we first measured the effect of FEZF1 on the mRNA and protein levels of β-catenin by RT-qPCR and western blot. The results showed that, although the mRNA level was not changed (Figure [6](#F6){ref-type="fig"}A and [6](#F6){ref-type="fig"}B, left), the level of β-catenin protein was reduced by FEZF1 knockdown in C33A cells, whereas increased by FEZF1 expression in HeLa cells (Figure [6](#F6){ref-type="fig"}A and [6](#F6){ref-type="fig"}B, right). In addition, we also measured the expression of *TCF7L2* gene which encodes TCF4, a common protein of the β-catenin-TCF complex, and two downstream effector genes, *JUN* and *CCND1*. As expected, the levels of these genes were decreased upon knockdown of FEZF1 in C33A cells, while increased by the expression of FEZF1 in HeLa cells (Figure [6](#F6){ref-type="fig"}C and [6](#F6){ref-type="fig"}D).

The two non-canonical pathways, the Wnt/ planar cell polarity (PCP) pathway and the Wnt/Ca^2+^ pathway, does not involve β-catenin. We selected four downstream effector genes in these two pathways and determined the effect of FEZF1 on their expression. The results showed that these genes were also downregulated in FEZF1 knockdown C33A cells, while upregulated in FEZF1-expressing HeLa cells (Figure [6](#F6){ref-type="fig"}E and [6](#F6){ref-type="fig"}F). Together, these results suggested that FEZF1 is a positive regulator of both canonical and non-canonical Wnt signaling pathways in cervical cancer cells.

Discussion
==========

Recurrence is a difficult clinical problem for cervical cancer, as most of patients with relapse are not curable [@B6], [@B7]. Optimization of primary treatment, based on the risk of recurrence, could be more rewarding than a deliberate post-treatment surveillance or aggressive salvage therapy [@B8]. Currently, clinicopathological factors, including tumor diameter, depth of stromal invasion, lymphvascular space invasion, parametrial extension, histologic variants, lymph node involvement and status of the resection margins, are used individually or in combination to evaluate the risk of recurrence in early-stage patients [@B17]. Patients who are deemed to be at high risk should receive adjuvant radiation therapy with or without chemotherapy after surgery [@B3]. However, the prognostic value of these clinicopathological factors is controversial, as these factors are lacking in sensitivity and reproducibility, which is mainly attributed to the wide variations in clinicopathological definitions and criteria.[@B17]. The squamous cell carcinoma antigen (SCC-Ag), a common serum protein marker, has also been assessed for recurrence prediction in cervical cancer [@B18]. Elevated post-treatment SCC-Ag level can precede clinical diagnosis in 46-92% of the cases, with a mean lead time ranging from 2 to 8 months, but the prognostic value of pre-treatment serum SCC-Ag on recurrence prediction is still debated [@B18]. In this study, we found that the level of FEZF1 in the primary tumor samples of cervical cancer was an independent diagnostic factor for recurrence using TCGA datasets. Patients with high level of FEZF1 were at significantly higher risk of recurrence (HR=3.479; 95% CI, 1.553-7.795; *P*=0.002) than patients with low level of FEZF1 expression (Table [2](#T2){ref-type="table"}). The introduction of FEZF1 as a predictive molecular marker for recurrence may facilitate the optimization of primary treatment and improve the overall outcomes of cervical cancer patients.

In addition, a significant increase of FEZF1 expression was observed in the primary tumor samples from patients with relapse (Figure [1](#F1){ref-type="fig"}C). In addition, expression of FEZF1 in HeLa cells enhanced cell proliferation, growth and migration (Figure [4](#F4){ref-type="fig"}), while knockdown of FEZF1 has the opposite effects on both C33A and SiHa cells (Figure [2](#F2){ref-type="fig"}). Meanwhile, FEZF1 knockdown also inhibited tumor growth*in vivo* (Figure [3](#F3){ref-type="fig"}). All these results demonstrated that FEZF1 plays an oncogenic role in cervical cancer.

The Wnt signaling pathway controls body axis patterning, cell fate specification, cell proliferation and cell migration during development, and aberrant activation of this pathway has been implicated in the development of many types of human cancers [@B19]-[@B21], including cervical cancer [@B22]. Increase of β-catenin, the hallmark of canonical Wnt pathway activation, has been reported to be an independent prognostic factor for the RFS and OS of cervical cancer patients [@B23]. Although FEZF1 does not bind to *CTNNB1* gene directly, many upstream pathway genes and several genes that control β-catenin stability are FEZF1 targets (Figure [5](#F5){ref-type="fig"}B). In this study, we found that the level of β-catenin protein was increased by the expression of FEZF1 in HeLa cells, while reduced by FEZF1 knockdown in C33A cells (Figure [6](#F6){ref-type="fig"}A and [6](#F6){ref-type="fig"}B). The results indicated that FEZF1 could activate the canonical Wnt pathway in cervical cancer cells. Moreover, the binding of FEZF1 to multiple key Wnt genes was also confirmed by ChIP assay (Figure [5](#F5){ref-type="fig"}C), and the effects of FEZF1 on their expression were examined by RT-qPCR (Figure [6](#F6){ref-type="fig"}C-F). These results showed that FEZF1 could bind to and activate *TCF7L2* gene which encodes TCF4, a common effector of β-catenin. Meanwhile, the upregulation of two important downstream effector genes, *JUN* and *CCND1*, further confirmed the positive regulatory role of FEZF1 in the canonical Wnt signaling pathways. Although not as well characterized as the canonical pathways, the two non-canonical pathways have also been found to be involved in cancer progression [@B24], [@B25]. In this study, we found that FEZF1 also bound to and activated key genes, such as *CaMK2D*, *PPP3CA* and *NFATC2*, in the non-canonical Wnt signaling pathways. Therefore, we propose that FEZF1 is a transcriptional activator for the Wnt signaling pathways in cervical cancer.

In summary, our results suggest that FEZF1 plays an oncogenic role in cervical cancer possibly by acting as a transcription activator of the Wnt signaling pathway. Since the Wnt signaling pathway has been considered as a promising therapeutic target in cancer [@B26], we suppose that FEZF1 may serve a potential target for preventing recurrence in cervical cancer. Importantly, we also introduced FEZF1 as a valuable predictive marker for cervical cancer recurrence, which may greatly improve the management of cervical cancer.
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![**High level of FEZF1 expression associated with cervical cancer recurrence in TCGA patients. (A)** Tukey boxplot showing FEZF1 expression in primary tumor samples from eight human cancer types. RNAseq data were obtained from TCGA and shown in log~2~(x+1) transformed RSEM normalized count. BRCA, breast cancer; CESC, cervical cancer; COADREAD, colon and rectal cancer; ESCA, esophageal cancer; LIHC, liver cancer; LUNG, lung cancer; PRAD, prostate cancer; STAD, stomach cancer. The numbers of samples with detectable FEZF1 expression, the total numbers of samples in certain cancer type and the percentage of FEZF1 expressing samples were indicated at the top. **(B)** Kaplan-Meier analysis of the OS (left) and RFS (right) of CESC patients from TCGA. Patients with high level of FEZF1 showed significantly poorer prognosis than patients with low level of FEZF1. **(C)** FEZF1 mRNA level was significantly higher in the primary tumor samples from CESC patients with recurrent disease than in the samples from patients without diagnosed recurrence. \**P* \< 0.05, \*\**P* \< 0.01.](jcav09p3929g001){#F1}

![**FEZF1 knockdown inhibited cervical cancer cell proliferation, growth and migration. (A)** RT-qPCR analysis showed efficient knockdown of FEZF1 by two independent shRNAs in C33A and SiHa cells. **(B)** Cell Counting Kit-8 assay demonstrated that cell proliferation was significantly decreased after FEZF1 knockdown in C33A and SiHa cells. **(C)** Colony formation assay showed that FEZF1 knockdown C33A and SiHa cells formed less colonies compared to their control cells. **(D)** Transwell migration assay revealed that the knockdown of FEZF1 attenuated the migration of C33A and SiHa cells. Data represent mean ±SD of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01.](jcav09p3929g002){#F2}

![**FEZF1 knockdown inhibited C33A cell growth *in vivo*.** Tumorigenesis assay was performed by subcutaneous injection of FEZF1 knockdown and control C33A cells (5×10^6^) into right flanks of BALB/c nude mice. **(A)** Tumor volumes were measured at the indicated days post-injection. **(B, C)** Tumors were photographed and weighted at 30 days. Data represent mean ±SD, n=6. \**P* \< 0.05, \*\**P* \< 0.01.](jcav09p3929g003){#F3}

![**Expression of FEZF1 promoted cell proliferation, growth and migration in HeLa cells. (A)** Western blot assay showed the ectopically expression of a FLAG tagged EGFP-FEZF1 fusion protein in HeLa cells. **(B)** Cell Counting Kit-8 assay demonstrated that cell proliferation was increased significantly in HeLa cells expressing FEZF1 protein. **(C)** Colony formation assay showed that FEZF1-expressing HeLa cells formed more colonies compared to the control cells. **(D)** Transwell migration assay revealed that expression of FEZF1 promoted cell migration in HeLa cells. Data represent mean ±SD of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01.](jcav09p3929g004){#F4}

![**FEZF1 bound to genes in the Wnt signaling pathway. (A)** GO enrichment analysis of the FEZF1-binding genes determined by a previous ChIP-seq assay in HEK293 cells. **(B)** Visualization of the previously determined FEZF1-binding genes in the Wnt signaling pathway using the Pathview package based on KEGG pathways. Dark gray indicates strong binding of FEZF1 to target genes. **(C)** ChIP assay demonstrated the binding of FEZF1 to the Wnt pathway genes in HeLa cells. B2M promoter region was used as a control for non-specific binding. Data represent mean ±SD of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01.](jcav09p3929g005){#F5}

![**FEZF1 activated the Wnt signaling pathway in cervical cancer cells. (A, B)** RT-qPCR and western blot analysis of β-catenin mRNA (left) and protein (right) levels in FEZF1 knockdown C33A and FEZF1-expressing HeLa cells. **(C, D)** RT-qPCR analysis of the expression of β-catenin downstream genes in FEZF1 knockdown C33A and FEZF1-expressing HeLa cells. The Wnt pathway nodes of corresponding genes are indicated below. **(E, F)** RT-qPCR analysis of selected non-canonical Wnt pathway genes in FEZF1 knockdown C33A cells and FEZF1-expressing HeLa cells. Data represent mean ±SD of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01.](jcav09p3929g006){#F6}

###### 

Univariate Cox proportional hazards regression analysis of the OS and RFS of the CESC patients from TCGA

  Characteristics            N               OS                          RFS                                    
  -------------------------- --------------- ----- --------------------- ------------- -- --------------------- -----------
  **Age**                    \<50            115   1                                      1                     
                             ≥50             79    1.340(0.741-2.423)    0.334            0.993(0.450-2.191)    0.986
  **Histologic type**        Squamous cell   160   1                                      1                     
                             Other types     34    0.845(0.356-2.005)    0.703            2.114(0.880-5.075)    0.094
  **Histologic grade**       G1-2            103   1                                      1                     
                             G3              68    0.748(0.360-1.554)    0.436            1.620(0.723-3.630)    0.241
                             GX^†^           23    1.748(0.789-3.872)    0.169            0.406(0.053-3.106)    0.385
  **Clinical stage**         I-II            153   1                                      1                     
                             III-IV          41    2.727(1.485-5.009)    0.001\*\*        1.036(0.388-2.763)    0.944
  **Pathological T stage**   T1-2            138   1                                      1                     
                             T3-4            21    4.390(2.037-9.459)    \<0.001\*\*      1.984(0.662-5.948)    0.221
                             TX^†^           35    2.618(1.315-5.212)    0.006\*\*        1.172(0.425-3.236)    0.759
  **Pathological N stage**   N0              86    1                                      1                     
                             N1              35    6.833(2.590-18.028)   \<0.001\*\*      5.164(1.874-14.230)   0.002\*\*
                             NX^†^           73    5.184(2.125-12.646)   \<0.001\*\*      1.855(0.660-5.215)    0.241
  **FEZF1**                  Low             147   1                                      1                     
                             High            47    2.032(1.077-3.834)    0.029\*\*        3.604(1.613-8.051)    0.002\*\*

Abbreviations: HR = hazard ratio; 95% CI = 95% confidence interval. ^†^GX, TX and NX: samples with unknown histological grade, tumor or node stage. \**P* \< 0.05, \*\**P* \< 0.01.

###### 

Multivariate Cox proportional hazards regression analysis of the OS and RFS of the CESC patients from TCGA

  Characteristics            N        OS                          RFS                                  
  -------------------------- -------- ----- --------------------- ----------- -- --------------------- -----------
  **Clinical stage**         I-II     153   1                                                          
                             III-IV   41    1.327(0.625-2.819)    0.462                                
  **Pathological T stage**   T1-2     138   1                                                          
                             T3-4     21    3.250(1.151-9.175)    0.026\*                              
                             TX^†^    35    2.302(0.811-6.532)    0.117                                
  **Pathological N stage**   N0       86    1                                    1                     
                             N1       35    5.732(2.137-15.374)   0.001\*\*      4.903(1.777-13.526)   0.002\*\*
                             NX^†^    73    2.375(0.753-7.494)    0.140          1.675(0.594-4.725)    0.330
  **FEZF1**                  Low      147   1                                    1                     
                             High     47    1.993(1.045-3.799)    0.036\*        3.479(1.553-7.795)    0.002\*\*

Abbreviations: HR = hazard ratio; 95% CI = 95% confidence interval. ^†^TX and NX: samples with unknown pathological tumor or node stage. \**P* \< 0.05, \*\**P* \< 0.01.
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